Loading…
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Legislative Progress
Momentum (last 30 days)
3
score
3 actions · 0 new cosponsors · 0 votes
Speed vs cohort
94pct
203d open
vs 10,940 other HR bills in the 119th — cohort avg 30d
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.
These links require the bill number to appear in the filing's source-reported specific issue text. Client expenses and lobbying-firm income are separate disclosure fields.
Filing registrants (3)
2026 · third_quarter · Veterans
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Client expense: Not reported · Firm income: $24,000
Presented to President.
Presented to President.
Message on Senate action sent to the House.
Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
Motion to reconsider laid on the table Agreed to without objection.
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
Considered as unfinished business. (consideration: CR H5159)
Bills with similar content found using semantic analysis.
Sources: Congress.gov
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Medical/Disease Research/Clinical Labs
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Client expense: Not reported · Firm income: $24,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Client expense: Not reported · Firm income: $24,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · third_quarter · Health Issues
H.R. 8205/S.4472 - Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 - All provisions. H.R. 7779 - HEALTHY BRAINS Act - All Provisions H.R. 3864 - Protecting Health Care for All Patients Act of 2025 All provisions related to the banning of use of the quality-adjusted Life year valuation metric in coverage and payment determinations under federal health care programs. H.Res.449/S.Res 266 - Supports the designation of ALS Awareness Month - All Provisions. H.R.2560/S.830 - Lifespan Respite Care Reauthorization Act of 2025 - Provisions relating to amending the Public Health Service Act to extend funding for respite care through 2030 and broadening the definition of 'family caregiver' to include all unpaid individuals.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
H.R. 8205/S.4472 - Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 - All provisions. H.R. 7779 - HEALTHY BRAINS Act - All Provisions H.R. 3864 - Protecting Health Care for All Patients Act of 2025 All provisions related to the banning of use of the quality-adjusted Life year valuation metric in coverage and payment determinations under federal health care programs. H.Res.449/S.Res 266 - Supports the designation of ALS Awareness Month - All Provisions. H.R.2560/S.830 - Lifespan Respite Care Reauthorization Act of 2025 - Provisions relating to amending the Public Health Service Act to extend funding for respite care through 2030 and broadening the definition of 'family caregiver' to include all unpaid individuals.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Client expense: Not reported · Firm income: $24,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Veterans
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Client expense: Not reported · Firm income: $24,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Health Issues
Research and treatment related to suicide prevention for veterans and patients with bipolar depression or PTSD; Amyotrophic lateral sclerosis (ALS); HR 8205/S 4472, Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026.
Client expense: Not reported · Firm income: $24,000
Government targets: HOUSE OF REPRESENTATIVES, SENATE
2026 · second_quarter · Medical/Disease Research/Clinical Labs
Expressed opposition to effort that caps indirect costs in NIH grants to 15% Supported efforts to add FSHD to the Peer Reviewed Medical Research Program Filed MDA Comments to U.S. Food and Drug Administration (FDA) on Impacts of Patient-Focused Drug Development Meetings RFI Led an ALS Organizations Letter to Speaker Johnson and Leader Jeffries Urging Swift Passage of ACT for ALS Reauthorization Act Sent an MDA Letter to Sens. Bill Cassidy and Bernie Sanders Re: Senate HELP Committee Markup of the ACT for ALS Reauthorization Act (S.4472) Filed MDA Comments to Centers for Disease Control and Prevention (CDC) on ICD-10 Code Classification of Ultra-Rare and Genetic Diseases Joined MDA Statement to Energy and Commerce Subcommittee on Health Markup of the ACT for ALS Reauthorization Act (H.R.8205) Filed MDA Comments to U.S. Food and Drug Administration on Plausible Mechanism Framework to Develop Individualized Therapies Sent MDA Comments in Support of ACT for ALS Reauthorization Act of 2026 Sent an MDA Statement on ACT for ALS Reauthorization Introduction Sent MDA Comments Re: Rare Disease Educational Materials from the Center for Drug Evaluation and Researchs Accelerating Rare Disease Cures Program and the Rare Disease Innovation Hub
Client expense: $60,000 · Firm income: Not reported
2026 · first_quarter · Health Issues
H.R. 8205 - To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes. All provisions. H.R. 7779 - HEALTHY BRAINS Act - All Provisions H.R. 3864 - Protecting Health Care for All Patients Act of 2025 All provisions related to the banning of use of the quality-adjusted Life year valuation metric in coverage and payment determinations under federal health care programs. General Discussions/Draft Language - Discussions around improving access, coverage, and prior authorization for treatments and drugs under Medicare, Medicare Advantage, and private insurance.
Client expense: $30,000 · Firm income: Not reported
Government targets: HOUSE OF REPRESENTATIVES, SENATE
At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
Placed on the Union Calendar, Calendar No. 637.
Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
Congress.gov source codes: 5000, H12200
Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
Committee Consideration and Mark-up Session Held
Forwarded by Subcommittee to Full Committee by Voice Vote.
Subcommittee Consideration and Mark-up Session Held
Referred to the Subcommittee on Health.
Referred to the House Committee on Energy and Commerce.
Introduced in House
Congress.gov source codes: 1000, Intro-H
| April 6, 2026 |
| Enrolled Bill | -- |
| Democratic |
| NJ |
| Andrew R. Garbarino | Republican | NY |
| Angie Craig | Democratic | MN |
| Bonnie Watson Coleman | Democratic | NJ |
| Brad Sherman | Democratic | CA |
| Bradley Scott Schneider | Democratic | IL |
| Brian K. Fitzpatrick | Republican | PA |
| Carol D. Miller | Republican | WV |
| Chellie Pingree | Democratic | ME |
| Chuck Edwards | Republican | NC |
| Danny K. Davis | Democratic | IL |
| Darin LaHood | Republican | IL |
| David G. Valadao | Republican | CA |
| David P. Joyce | Republican | OH |
| David Rouzer | Republican | NC |
| Debbie Dingell | Democratic | MI |
| Deborah K. Ross | Democratic | NC |
| Don Bacon | Republican | NE |
| Donald G. Davis | Democratic | NC |
| Doris O. Matsui | Democratic | CA |
| Eleanor Holmes Norton | Democratic | DC |
| Emanuel Cleaver | Democratic | MO |
| Eric Sorensen | Democratic | IL |
| Eugene Simon Vindman | Democratic | VA |
| George Latimer | Democratic | NY |
| George Whitesides | Democratic | CA |
| Glenn Thompson | Republican | PA |
| Greg Landsman | Democratic | OH |
| Greg Stanton | Democratic | AZ |
| Gus M. Bilirakis | Republican | FL |
| Gwen Moore | Democratic | WI |
| Herbert C. Conaway, Jr. | Democratic | NJ |
| J. Luis Correa | Democratic | CA |
| Jahana Hayes | Democratic | CT |
| Jake Auchincloss | Democratic | MA |
| James A. Himes | Democratic | CT |
| Janelle S. Bynum | Democratic | OR |
| Janice D. Schakowsky | Democratic | IL |
| Jason Crow | Democratic | CO |
| Jay Obernolte | Republican | CA |
| Jeff Hurd | Republican | CO |
| Jefferson Van Drew | Republican | NJ |
| Joe Wilson | Republican | SC |
| John B. Larson | Democratic | CT |
| John H. Rutherford | Republican | FL |
| John R. Carter | Republican | TX |
| Jonathan L. Jackson | Democratic | IL |
| Josh Gottheimer | Democratic | NJ |
| Josh Riley | Democratic | NY |
| Joyce Beatty | Democratic | OH |
| Julia Letlow | Republican | LA |
| Ken Calvert | Republican | CA |
| Kim Schrier | Democratic | WA |
| Lauren Underwood | Democratic | IL |
| Madeleine Dean | Democratic | PA |
| Marc A. Veasey | Democratic | TX |
| Marcy Kaptur | Democratic | OH |
| Maria Elvira Salazar | Republican | FL |
| Mario Diaz-Balart | Republican | FL |
| Mark Alford | Republican | MO |
| Mark E. Amodei | Republican | NV |
| Mary Gay Scanlon | Democratic | PA |
| Melanie A. Stansbury | Democratic | NM |
| Michael Guest | Republican | MS |
| Michael T. McCaul | Republican | TX |
| Mike Bost | Republican | IL |
| Mike Thompson | Democratic | CA |
| Nick LaLota | Republican | NY |
| Nikki Budzinski | Democratic | IL |
| Paul Tonko | Democratic | NY |
| Pete Sessions | Republican | TX |
| Raja Krishnamoorthi | Democratic | IL |
| Randy K. Weber, Sr. | Republican | TX |
| Rashida Tlaib | Democratic | MI |
| Ritchie Torres | Democratic | NY |
| Robert B. Aderholt | Republican | AL |
| Robert J. Wittman | Republican | VA |
| Robin L. Kelly | Democratic | IL |
| Sanford D. Bishop, Jr. | Democratic | GA |
| Sarah McBride | Democratic | DE |
| Scott DesJarlais | Republican | TN |
| Scott H. Peters | Democratic | CA |
| Sean Casten | Democratic | IL |
| Seth Magaziner | Democratic | RI |
| Stephanie I. Bice | Republican | OK |
| Stephen F. Lynch | Democratic | MA |
| Steve Cohen | Democratic | TN |
| Steve Womack | Republican | AR |
| Suzan K. DelBene | Democratic | WA |
| Suzanne Bonamici | Democratic | OR |
| Terri A. Sewell | Democratic | AL |
| Thomas R. Suozzi | Democratic | NY |
| Tim Moore | Republican | NC |
| Tim Walberg | Republican | MI |
| Timothy M. Kennedy | Democratic | NY |
| Tom Cole | Republican | OK |
| Tracey Mann | Republican | KS |
| Troy A. Carter | Democratic | LA |
| Valerie P. Foushee | Democratic | NC |
| Young Kim | Republican | CA |
Government targets: Centers For Disease Control & Prevention (CDC), Centers For Medicare and Medicaid Services (CMS), Defense, Dept of (DOD), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Health Resources & Services Administration (HRSA), Natl Institutes of Health (NIH), SENATE